Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models
09-Feb-2010
- Switzerland
ADX71943 is an orally available positive allosteric modulator (PAM) of the GABA(B) receptor that has potential for treatment of osteoarthritis pain and chronic nociceptive pain as well as other indications. ADX71943 has a good developability profile and is expected to enter clinical testing in the fourth quarter 2010.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
FDA Clears IND for Cytogen's Monoclonal Antibody for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
Go to page
Depigmentation
Go to page
First of 100 Arab Human Genomes Sequenced by Saudi Biosciences, Beijing Genomics Institute Shenzhen, and CLC bio
Go to page
Pion Inc. - Billerica, USA
Go to page
Pentazocine
Go to page
ProMetic and Serono Sign a Development and Collaboration Agreement - Development revenues for ProMetic of up to £550,000 (approx. $C1.3M)
Go to page
Basilea announces change in its management structure
Go to page
ProMetic Announces Contract with GlaxoSmithKline
Go to page
Wolf Verpackungsmaschinen GmbH - Lich, Germany
Go to page
Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University - Development of a monoclonal antibody for the treatment of Alzheimer’s disease
Go to page
Winkler AG - Heidelberg, Germany
Go to page